// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Utility of annual screening serum testosterone level in men on surveillance for clinical stage I testicular cancer.

Eric Winquist - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Androgen Tear

Immediate-term Chemotherapy-Related Cognitive Impairment (CRCI) Following Administration of Intravenous (IV) Chemotherapy.

Omar Farooq Khan - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Evaluating an Educational Intervention to Alleviate Distress among Men with Newly-Diagnosed Prostate Cancer and their Partners.

Lindsay Hedden - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A preliminary evaluation of the TrueNTH androgen deprivation therapy educational program.

Erik Wibowo - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

The impact of neurocognitive function on health utility scores (HUS) in Stage 4 (S4) lung cancer patients (pts) with and without brain metastases (BrM).

Brandon C Tse - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)

T.Dalvi - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Olaparib

IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC)

D.Miles - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Atezolizumab

EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)

M.Martin Jimenez - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Anastrozole

Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients

E.Segelov - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

panitumumab

nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial

P.A.Philip - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Gemcitabine

Sarcopenia, myosteatosis, and weight loss as determinants of survival and toxicity in patients with resectable esophageal and gastroesophageal junction (GEJ) cancer receiving preoperative chemoradiotherapy (CRT)

A.G.Lui - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Carboplatin

Iron deficiency anemia in gastric cancer: A Canadian single site retrospective cohort study

C.Brezden-Masley - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Accuracy and prognostic significance of oncologists’ estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer

A.Vasista - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Regorafenib

Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database

H.H.Samawi - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Sorafenib

Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)

F.Portales - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Gemcitabine

Prognosis of familial pancreatic cancer (FPC): A matched case analysis

G.M.O'Kane - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Comparisons of outcomes of patients with advanced pancreatic cancer (APC) treated with FOLFIRINOX (FX) versus gemcitabine and nab-paclitaxel (GN): A population-based cohort study

N.Papneja - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Gemcitabine

Prognostic value of neutrophil-lymphocyte ratio in first line treatment for metastatic pancreatic adenocarcinoma

Y.S.Rho - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Impact of advances in systemic chemotherapy for unresectable pancreatic ductal adenocarcinoma (PDAC) in Alberta, Canada

R.Lee-Ying - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)

R.S.Finn - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Copyright © 2026. QuantiNova All rights reserved